On January 7, 2025 Pillar Biosciences, Inc. reported the company has entered into a strategic five-year licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) for its proprietary OncoKB precision medicine knowledgebase (Press release, Pillar Biosciences, JAN 7, 2025, View Source [SID1234649478]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OncoKB is the first somatic human variant database to receive FDA recognition. It contains information about the biological effects and possible treatment implications of specific cancer gene alterations.

The strategic licensing agreement enables immediate extension of the capability of Pillar Biosciences PiVAT bioinformatics platform for seamless patient genomic reporting through linkage to OncoKB.

"Our PiVAT secondary genomics analysis platform was purpose built for our SLIMamp chemistry to enable the most accurate genomic calling for our kitted RUO and IVD products," said ShiPing Zou, Senior Director of Global Product Management, Pillar Biosciences. "While Pillar’s panels are agnostic to which tertiary reporting our clients have implemented, it is important we ensure that downstream genomic reporting is not a bottleneck to assay validation and implementation and that we continue to provide timely access to actionable information to our customers and the patients they serve."